Affiliate disclosure: As an Amazon Associate, this site earns from qualifying purchases linked in this article.
Ready to buy? Check current prices on Amazon and compare deals before you decide.
Navigating the changes of menopause often involves managing symptoms such as hot flashes and disrupted sleep. While hormonal therapy is an option for some, many women seek or require non-hormonal approaches.
Fortunately, several prescription non-hormonal options have been studied for their potential to help manage these common menopausal experiences. This article provides an overview of these evidence-based choices, focusing on how they may help alleviate hot flashes and improve sleep.
Understanding Hot Flashes and Sleep Disturbances in Menopause
Hot flashes, also known as vasomotor symptoms (VMS), are a hallmark of menopause, characterized by sudden feelings of heat, sweating, and sometimes flushing [1]. These symptoms can range in frequency and intensity, significantly impacting daily life and sleep quality [1]. Night sweats, a form of VMS occurring during sleep, often lead to waking and can contribute to chronic sleep disturbances [1].
Sleep disruptions during menopause are multifaceted. Beyond night sweats, hormonal shifts can influence sleep architecture, potentially leading to insomnia, increased awakenings, and a reduction in restorative sleep. Addressing these symptoms is crucial for overall well-being and quality of life during this transitional period.
Before you buy: black cohosh and liver safety. Estroven Sleep Cool contains black cohosh. Products labelled as black cohosh have been implicated in cases of clinically apparent acute liver injury, some of them severe enough to lead to emergency liver transplantation or death, and the National Institute of Diabetes and Digestive and Kidney Diseases maintains a dedicated LiverTox monograph covering those reports. Causality is contested rather than settled, and a structured review of the early cases concluded it was not established in any of them. What the sources agree on is the practical guidance: anyone with existing liver disease should avoid black cohosh, and anyone taking it should stop and seek medical care if jaundice, dark urine, unusual fatigue or right-sided abdominal pain develops. Our evidence review of black cohosh safety works through the case reports and the causality assessments.
Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
SSRIs and SNRIs are types of antidepressant medications that have also shown benefit in managing menopausal hot flashes, even in women without depression [2]. These medications are thought to influence the thermoregulatory center in the brain, helping to stabilize body temperature control [3].
Paroxetine, an SSRI, is specifically approved for the management of menopausal VMS [4]. Studies indicate that SSRIs and SNRIs can reduce both the frequency and severity of hot flashes[5][2]. Common SNRIs like venlafaxine have also demonstrated efficacy in addressing VMS[6][7]. These medications can be particularly relevant for women who cannot or prefer not to use hormonal therapy, including breast cancer survivors[6][8].
Beyond hot flashes, some women may experience improvements in sleep quality while taking these medications, though this is often secondary to the reduction in night sweats rather than a direct sleep-inducing effect. Potential side effects can include nausea, dry mouth, and dizziness, and these should be discussed with a healthcare provider [5].
Gabapentin and Pregabalin
Gabapentin, an anticonvulsant medication, has been found to be effective in reducing the frequency and severity of hot flashes [7]. It is thought to influence neurotransmitters involved in thermoregulation. This medication has been used as a non-hormonal option for VMS, including in women who have contraindications to hormonal therapy[6][9].
A notable benefit of gabapentin is its potential to improve sleep. Drowsiness is a common side effect, which can be harnessed to aid sleep when the medication is taken at bedtime [6]. Pregabalin, a related medication, has also shown similar efficacy in managing hot flashes and may offer sleep benefits due to its sedating properties [9]. Common side effects of both medications can include dizziness and somnolence [9].
These medications are often considered for women experiencing significant sleep disturbances alongside hot flashes, especially when other options are not suitable.
Oxybutynin
Oxybutynin, an anticholinergic medication primarily used for overactive bladder, has also demonstrated effectiveness in reducing hot flashes[1][4]. It works by blocking muscarinic receptors, which play a role in sweating and thermoregulation. Studies indicate that oxybutynin can lead to a reduction in both the frequency and intensity of VMS [9].
While not directly a sleep aid, by reducing the occurrence of night sweats, oxybutynin may indirectly contribute to more uninterrupted sleep. Potential side effects include dry mouth, constipation, and blurred vision [9]. It’s important to discuss these with a healthcare provider, especially considering potential interactions or existing health conditions.
Fezolinetant: A Newer Non-Hormonal Option
Fezolinetant represents a newer class of non-hormonal medication for VMS. It is a neurokinin 3 (NK3) receptor antagonist that works by modulating neuronal activity in the brain’s thermoregulatory center [1]. This mechanism is distinct from other non-hormonal options and targets the specific neural pathways involved in hot flash generation [10].
Clinical trials have shown fezolinetant to be effective in reducing the frequency and severity of hot flashes[1][4]. It has been compared favorably to other non-hormonal therapies in terms of efficacy for VMS [10]. By significantly reducing hot flashes, particularly night sweats, fezolinetant may contribute to improved sleep quality for many women. Common side effects reported include abdominal pain and diarrhea [4].
References
- Management of Menopausal Symptoms: A Review. JAMA, 2023
- Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. The Journal of the Oklahoma State Medical Association, 2017
- Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treatments in endocrinology, 2006
- The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause (New York, N.Y.), 2023
- The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. Journal of the American Association of Nurse Practitioners, 2015
- Management of hot flashes in breast cancer survivors and men with prostate cancer. Current oncology reports, 2004
- Hormonal and nonhormonal treatment of vasomotor symptoms. Obstetrics and gynecology clinics of North America, 2015
- Managing menopause after cancer. Lancet (London, England), 2024
- Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms. Cureus, 2024
- Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. Menopause (New York, N.Y.), 2024
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
